查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954259

病毒載體生產市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終用戶、製程、階段、設備分類

Viral Vector Production Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Equipment
出版日期: | 出版商: Global Insight Services | 英文 312 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

病毒載體生產市場預計將從2024年的76億美元成長到2034年的457億美元，複合年成長率約為22.1%。病毒載體生產市場涵蓋用於基因治療、疫苗和細胞治療的病毒載體的生產和供應。這些載體對於將遺傳物質遞送到細胞中至關重要，從而實現治療性介入。生物技術的進步和對個人化醫療投資的增加是推動市場成長的主要因素。關鍵趨勢包括可擴展生產技術的開發和對創新治療方法的監管支持，這些因素正在促進市場成長並形成差異化競爭優勢。

病毒載體生產市場持續穩定成長，主要受基因治療和疫苗研發進展的推動。基因治療領域憑藉臨床試驗的增加和FDA核准的進展，成為成長最快的細分市場。慢病毒載體因其能夠整合到宿主基因組中，確保長期表達，佔據市場主導地位。腺結合病毒載體因其安全性高且無致病性而備受推崇，是成長第二快的細分市場。在疫苗研發中，病毒載體對於有效遞送抗原至關重要。腺病毒載體細分市場佔據主導地位，尤其是在新冠疫苗生產領域，這主要得益於其快速的生產能力。雖然逆轉錄病毒載體的應用相對較少，但其在腫瘤學領域的潛在應用正在推動市場成長。生物技術公司與學術機構之間日益密切的合作正在推動創新，並提高載體的設計和生產效率。持續投資於可擴展的生產技術至關重要，這能夠確保市場的持續發展，並滿足未來的治療需求。

市場區隔
類型 腺病毒載體、慢病毒載體、腺結合病毒載體、逆轉錄病毒載體
產品 質體，表現系統
服務 上游工程、下游製程、品管與測試
科技 轉染，轉導
應用領域 基因療法、疫苗學、細胞療法、癌症研究
最終用戶 生物製藥公司、研究機構和契約製造組織
過程 發酵和精煉
步 臨床前、臨床和商業化生產
裝置 生物反應器、離心機、過濾系統

病毒載體生產市場正經歷市場佔有率、定價策略和產品創新方面的動態變化。各公司正透過尖端病毒載體解決方案來增強產品系列，以滿足基因治療和疫苗研發的激增需求。先進生物製程技術的趨勢正在影響定價結構，使其更加重視成本效益和擴充性。新產品的推出正在建立療效和安全性的新標準，進一步加劇了市場競爭。這種演變反映了業界為滿足不斷成長的臨床和商業性需求所做的努力。病毒載體生產市場的競爭日益激烈，主要參與者都在尋求技術優勢。基準分析顯示，旨在增強生產能力的策略聯盟和併購正成為主流。法規結構，尤其是在美國和歐洲，對於確保合規性和品質標準以及塑造市場動態至關重要。亞太地區的新興市場在有利的政府政策和不斷成長的醫療保健投資的推動下，提供了盈利的機會。預計在創新和策略聯盟的支持下，該市場將實現強勁成長。

主要趨勢和促進因素：

受基因療法和疫苗需求不斷成長的推動，病毒載體生產市場正經歷強勁成長。生物技術的進步催生了更有效率、擴充性的病毒載體生產技術。遺傳性疾病和感染疾病的日益增多，對創新療法的需求也進一步推動了這一趨勢。關鍵趨勢包括採用一次性技術，這提高了生產的柔軟性並降低了污染風險。此外，人工智慧 (AI) 和自動化技術在生產流程中的應用，也提高了營運效率和產量。旨在擴大產能和加快新治療方法上市速度的策略聯盟和夥伴關係也激增。推動市場成長的因素包括製藥公司的大量投資以及政府對先進治療藥物 (ATMP) 的支持。個人化醫療和客製化治療的推進，進一步刺激了對病毒載體的需求。能夠在保證品質和符合監管要求的前提下擴大生產規模的公司，將更有機會掌握這些盈利的機會。不斷擴充的細胞和基因療法研發管線有望顯著改善醫療保健效果，凸顯了市場的巨大潛力。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 腺病毒載體
    • 慢病毒載體
    • 腺結合病毒載體
    • 逆轉錄病毒載體
  • 市場規模及預測：依產品分類
    • 質體
    • 表達系統
  • 市場規模及預測：依服務分類
    • 上游工程
    • 下游工藝
    • 品管和測試
  • 市場規模及預測：依技術分類
    • 轉染
    • 轉導
  • 市場規模及預測：依應用領域分類
    • 基因治療
    • 疫苗學
    • 細胞療法
    • 癌症研究
  • 市場規模及預測：依最終用戶分類
    • 生物製藥公司
    • 研究所
    • 契約製造組織（CMO）
  • 市場規模及預測：依製程分類
    • 發酵
    • 純化
  • 市場規模及預測：依發展階段分類
    • 臨床前階段
    • 臨床
    • 商業的
  • 市場規模及預測：依設備分類
    • 生物反應器
    • 離心機
    • 過濾系統

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Oxford Biomedica
  • Brammer Bio
  • Genethon
  • VGXI
  • Bio NTech
  • Sirion Biotech
  • Cobra Biologics
  • Cell and Gene Therapy Catapult
  • Yposkesi
  • Mol Med
  • Fin Vector
  • Lonza
  • Batavia Biosciences
  • Novasep
  • Vigene Biosciences
  • Aldevron
  • Bluebird Bio
  • uni Qure
  • Touchlight Genetics
  • Repligen

第9章：關於我們

簡介目錄
Product Code: GIS31585

Viral Vector Production Market is anticipated to expand from $7.6 billion in 2024 to $45.7 billion by 2034, growing at a CAGR of approximately 22.1%. The Viral Vector Production Market encompasses the manufacturing and supply of viral vectors used in gene therapy, vaccines, and cell therapy. These vectors are pivotal in delivering genetic material into cells, facilitating therapeutic interventions. The market is driven by advancements in biotechnology and increased investment in personalized medicine. Key trends include the development of scalable production technologies and regulatory support for innovative therapies, propelling growth and fostering competitive differentiation.

The Viral Vector Production Market is experiencing robust expansion, primarily propelled by advancements in gene therapy and vaccine development. The gene therapy segment stands out as the top-performing sub-segment, driven by increasing clinical trials and FDA approvals. Lentiviral vectors are leading due to their ability to integrate into the host genome, ensuring long-term expression. Adeno-associated viral vectors are the second highest-performing, favored for their safety profile and non-pathogenic nature. In the vaccine development segment, viral vectors are crucial for delivering antigens effectively. The adenoviral vector sub-segment dominates, especially in COVID-19 vaccine production, due to its rapid manufacturing capabilities. Retroviral vectors, although less prominent, hold potential in oncology applications, contributing to market growth. The rise in partnerships between biotech firms and academic institutions is fostering innovation, enhancing vector design and production efficiency. Continuous investment in scalable manufacturing technologies is pivotal, ensuring the market's sustained evolution and addressing future therapeutic demands.

Market Segmentation
TypeAdenoviral Vectors, Lentiviral Vectors, Adeno-associated Viral Vectors, Retroviral Vectors
ProductPlasmids, Expression Systems
ServicesUpstream Processing, Downstream Processing, Quality Control & Testing
TechnologyTransfection, Transduction
ApplicationGene Therapy, Vaccinology, Cell Therapy, Cancer Research
End UserBiopharmaceutical Companies, Research Institutes, Contract Manufacturing Organizations
ProcessFermentation, Purification
StagePreclinical, Clinical, Commercial
EquipmentBioreactors, Centrifuges, Filtration Systems

The Viral Vector Production Market is witnessing a dynamic shift in market share, pricing strategies, and product innovations. Companies are enhancing their portfolios with cutting-edge viral vector solutions, addressing the burgeoning demand in gene therapy and vaccine development. The trend towards advanced bioprocessing techniques is influencing pricing structures, with a focus on cost-efficiency and scalability. New product launches are setting benchmarks in efficacy and safety, further propelling market competitiveness. This evolution reflects the industry's commitment to meeting the growing clinical and commercial needs. Competition in the viral vector production market is intensifying, with key players striving for technological supremacy. Benchmarking reveals a landscape dominated by strategic partnerships and mergers, aiming to bolster production capabilities. Regulatory frameworks, particularly in the U.S. and Europe, are pivotal in shaping market dynamics, ensuring compliance and quality standards. Emerging markets in Asia-Pacific present lucrative opportunities, driven by favorable government policies and increasing healthcare investments. The market is poised for robust growth, underpinned by innovation and strategic collaborations.

Geographical Overview:

The viral vector production market is witnessing substantial growth across diverse regions, each exhibiting unique opportunities. North America leads the market, propelled by robust biotechnology and pharmaceutical sectors. The region benefits from substantial R&D investments and advanced healthcare infrastructure. The United States, in particular, is a key player, driving innovation and production capabilities. Europe follows, characterized by strong regulatory frameworks and a focus on gene therapy advancements. The United Kingdom and Germany are at the forefront, fostering a conducive environment for viral vector development. In the Asia Pacific region, the market is expanding rapidly due to increasing healthcare investments and a burgeoning biotechnology industry. China and India are emerging as significant contributors, with growing capabilities in biopharmaceutical manufacturing. Latin America and the Middle East & Africa represent emerging growth pockets. In Latin America, Brazil is gaining traction with investments in biotechnology. Meanwhile, the Middle East & Africa are recognizing the potential of viral vectors in addressing regional healthcare challenges, spurring market interest.

Global tariffs and geopolitical tensions are significantly influencing the Viral Vector Production Market, particularly in East Asia. Japan and South Korea are bolstering their biotech sectors to mitigate reliance on foreign imports, while China is rapidly advancing its domestic capabilities in response to Western export controls. Taiwan, crucial for biotech components, is navigating geopolitical pressures with strategic partnerships. The global market for viral vectors, integral to gene therapies and vaccines, is expanding robustly, driven by innovation and increased healthcare spending. By 2035, the market is expected to witness substantial growth, contingent on resilient supply chains and regional collaborations. Middle East conflicts exacerbate global supply chain vulnerabilities and energy price volatility, potentially impacting production costs and timelines for biotech projects worldwide.

Key Trends and Drivers:

The Viral Vector Production Market is experiencing robust growth due to increasing demand for gene therapies and vaccines. Advances in biotechnology have paved the way for more efficient and scalable viral vector production techniques. This trend is further bolstered by the rising prevalence of genetic disorders and infectious diseases, necessitating innovative treatment solutions. Key trends include the adoption of single-use technologies that enhance manufacturing flexibility and reduce contamination risks. Additionally, the integration of artificial intelligence and automation in production processes is streamlining operations and improving yield efficiencies. The market is also witnessing a surge in strategic collaborations and partnerships aimed at expanding production capacities and accelerating time-to-market for new therapies. Drivers of market growth include substantial investments from pharmaceutical companies and government initiatives supporting advanced therapy medicinal products (ATMPs). The push towards personalized medicine and tailored treatment approaches is further amplifying the demand for viral vectors. Companies that can scale production while maintaining quality and regulatory compliance are poised to capitalize on these lucrative opportunities. The expanding pipeline of cell and gene therapies underscores the market's potential, promising significant advancements in healthcare outcomes.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Adenoviral Vectors
    • 4.1.2 Lentiviral Vectors
    • 4.1.3 Adeno-associated Viral Vectors
    • 4.1.4 Retroviral Vectors
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Plasmids
    • 4.2.2 Expression Systems
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Upstream Processing
    • 4.3.2 Downstream Processing
    • 4.3.3 Quality Control & Testing
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Transfection
    • 4.4.2 Transduction
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Gene Therapy
    • 4.5.2 Vaccinology
    • 4.5.3 Cell Therapy
    • 4.5.4 Cancer Research
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biopharmaceutical Companies
    • 4.6.2 Research Institutes
    • 4.6.3 Contract Manufacturing Organizations
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Fermentation
    • 4.7.2 Purification
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical
    • 4.8.3 Commercial
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 Bioreactors
    • 4.9.2 Centrifuges
    • 4.9.3 Filtration Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Oxford Biomedica
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Brammer Bio
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Genethon
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 VGXI
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Bio NTech
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sirion Biotech
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cobra Biologics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cell and Gene Therapy Catapult
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Yposkesi
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Mol Med
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Fin Vector
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Lonza
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Batavia Biosciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Novasep
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Vigene Biosciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Aldevron
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bluebird Bio
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 uni Qure
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Touchlight Genetics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Repligen
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us